Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says

MT Newswires Live

Mar 05, 2025

Chimerix (CMRX) was a prime acquisition candidate for Jazz Pharmaceuticals (JAZZ) due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.

Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.

There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.

Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.

Shares of Chimerix were up almost 69% in recent trading.

Price: 8.43, Change: +3.47, Percent Change: +69.96

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517462649"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517462649\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517462649?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517462649","market":"sh","top_or_hot":-1,"title":"Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Chimerix (CMRX) was a prime acquisition candidate for Jazz Pharmaceuticals (JAZZ) due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.</p><p>Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.</p><p>There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.</p><p>Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.</p><p>Shares of Chimerix were up almost 69% in recent trading.</p><p>Price: 8.43, Change: +3.47, Percent Change: +69.96</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-05 23:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Chimerix (CMRX) was a prime acquisition candidate for Jazz Pharmaceuticals (JAZZ) due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.</p><p>Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.</p><p>There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.</p><p>Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.</p><p>Shares of Chimerix were up almost 69% in recent trading.</p><p>Price: 8.43, Change: +3.47, Percent Change: +69.96</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517462649","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517462649","pubTimestamp":1741189907,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chimerix  was a prime acquisition candidate for Jazz Pharmaceuticals  due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.Shares of Chimerix were up almost 69% in recent trading.Price: 8.43, Change: +3.47, Percent Change: +69.96","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4583":"猴痘概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","CMRX":"Chimerix Inc.","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4532":"文艺复兴科技持仓","JAZZ":"爵士制药","BK4139":"生物科技","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Wedbush表示，由于Dordaviprone，Chimerix成为Jazz Pharmaceuticals的主要收购候选者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMRX":1,"JAZZ":0.9},"content_text":"Chimerix (CMRX) was a prime acquisition candidate for Jazz Pharmaceuticals (JAZZ) due to dordaviprone's unique positioning and likely near-term approval to treat H3-K27M mutant glioma, Wedbush said in a note Wednesday.Jazz said Wednesday it agreed to acquire Chimerix for $8.55 per share in an all-cash deal, about a 72% premium over its previous closing price and in-line with the estimated fair value of dordaviprone, the investment firm said.There does not appear to be any antitrust issues because Jazz does not have a presence glioma, Wedbush said.Wedbush downgraded Chimerix to neutral from outperform and raised its price target to $8.55, reflecting the cash tender offer.Shares of Chimerix were up almost 69% in recent trading.Price: 8.43, Change: +3.47, Percent Change: +69.96","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}